-transparent.png){kind=logo}
The reinforcing properties of zopiclone (3.75 mg) and triazolam (0.25 mg) and their side effects were studied in a double-blind crossover design, followed by forced choice in 40 volunteers taken from a population of chronic alcoholic inpatients who had just completed withdrawal from alcohol. After initial interview when the physician checked if the inclusion and exclusion criteria were met, patients were submitted to the following assessments: profile of mood states (POMS), ARCI subscales (items of scales No. 452, 129, 125, and 52), drug record form and vital signs, SESI (side effect checklist), preference form, subjective effect scale (subscale 220 of the ARCI), and withdrawal assessment. No difference between the drugs could be found on the POMS, ARCI or in the drug intake. There was a difference in patients' drug preference for triazolam in comparison to zopiclone. Zopiclone, like triazolam, may induce some feelings similar to those obtained with alcohol. Side effects noticed by patients were of mild to moderate degree and harmless.
L P Bechelli, and
F Navas, and
S A Pierangelo
January 1987,
European journal of clinical pharmacology,
L P Bechelli, and
F Navas, and
S A Pierangelo
January 1988,
L'Encephale,
L P Bechelli, and
F Navas, and
S A Pierangelo
January 1990,
European journal of clinical pharmacology,
L P Bechelli, and
F Navas, and
S A Pierangelo
January 1983,
Pharmacology,
L P Bechelli, and
F Navas, and
S A Pierangelo
January 1982,
International pharmacopsychiatry,
L P Bechelli, and
F Navas, and
S A Pierangelo
January 1994,
Neuropsychobiology,
L P Bechelli, and
F Navas, and
S A Pierangelo
April 1990,
International clinical psychopharmacology,
L P Bechelli, and
F Navas, and
S A Pierangelo
April 1990,
International clinical psychopharmacology,
L P Bechelli, and
F Navas, and
S A Pierangelo
January 1987,
Neuropsychobiology,
L P Bechelli, and
F Navas, and
S A Pierangelo
April 1990,
International clinical psychopharmacology,
